Assignee
SUMITOMO PHARMA ONCOLOGY INC
US·11 granted patents·14 pending applications·17 citations·filing 2018–2024
Top patents by PatentIndex Score
25 records- 0195US11530231B2CDK9 inhibitors and polymorphs thereof for use as agents for treatment of cancerSUMITOMO PHARMA ONCOLOGY INC·Filed 2021·Granted Dec 20, 2022·5 cites·21 claims
- 0290US11497756B2Treatment regimen for cancers that are insensitive to BCL-2 inhibitors using the MCL-1 inhibitor alvocidibSUMITOMO PHARMA ONCOLOGY INC·Filed 2018·Granted Nov 15, 2022·4 cites·18 claims
- 0387US11793802B2Treatment of acute myeloid leukemia (AML) with venetoclax failureSUMITOMO PHARMA ONCOLOGY INC·Filed 2020·Granted Oct 24, 2023·8 cites·20 claims
- 0482US2024173319A1Solid dose pharmaceutical compositionSUMITOMO PHARMA ONCOLOGY INC·Filed 2023·Application pending·0 cites
- 0580US2023390288A1Solid dose pharmaceutical compositionSUMITOMO PHARMA ONCOLOGY INC·Filed 2023·Application pending·0 cites
- 0679US2025197432A1CDK9 Inhibitors and Polymorphs Thereof For Use As Agents For Treatment of CancerSUMITOMO PHARMA ONCOLOGY INC·Filed 2024·Application pending·0 cites
- 0777US12338261B2Alvocidib prodrugs having increased bioavailabilitySUMITOMO PHARMA ONCOLOGY INC·Filed 2021·Granted Jun 24, 2025·0 cites·10 claims
- 0877US2023181586A1Solid dose pharmaceutical compositionSUMITOMO PHARMA ONCOLOGY INC·Filed 2023·Application pending·0 cites
- 0976US12077554B2CDK9 inhibitors and polymorphs thereof for use as agents for treatment of cancerSUMITOMO PHARMA ONCOLOGY INC·Filed 2022·Granted Sep 3, 2024·0 cites·20 claims
- 1074US2024075033A1Alk5 inhibitors for treating myelodysplastic syndromeSUMITOMO PHARMA ONCOLOGY INC·Filed 2023·Application pending·0 cites
- 1169US11414394B2Process for producing a hydrate of a hydrochloride salt of 2,2′-((((((2-acetylnaphtho[2,3-b]furan-4,9-diyl)bis(oxy))bis(carbonyl))bis(azanediyl))bis(ethane-2,1-diyl))bis(azanediyl))diacetic acidSUMITOMO PHARMA ONCOLOGY INC·Filed 2020·Granted Aug 16, 2022·0 cites·8 claims
- 1268US2023000864A1Solid dose pharmaceutical compositionSUMITOMO PHARMA ONCOLOGY INC·Filed 2020·Application pending·0 cites
- 1368US2023165857A1Axl kinase inhibitors and use of the sameSUMITOMO PHARMA ONCOLOGY INC·Filed 2022·Application pending·0 cites
- 1468US2023233557A1Formulations comprising heterocyclic protein kinase inhibitorsSUMITOMO PHARMA ONCOLOGY INC·Filed 2022·Application pending·0 cites
- 1563US11471456B2Formulations comprising heterocyclic protein kinase inhibitorsSUMITOMO PHARMA ONCOLOGY INC·Filed 2020·Granted Oct 18, 2022·0 cites·23 claims
- 1662US11400091B2AXL kinase inhibitors and use of the sameSUMITOMO PHARMA ONCOLOGY INC·Filed 2020·Granted Aug 2, 2022·0 cites·36 claims
- 1761US2024360135A1Imidazo[1,2-b]pyridazinyl compounds and uses thereofSUMITOMO PHARMA ONCOLOGY INC·Filed 2022·Application pending·0 cites
- 1861US2022339172A1Methods for treating castration-resistant and castration-sensitive prostate cancerSUMITOMO PHARMA ONCOLOGY INC·Filed 2021·Application pending·0 cites
- 1958US11712433B2Compositions comprising PKM2 modulators and methods of treatment using the sameSUMITOMO PHARMA ONCOLOGY INC·Filed 2020·Granted Aug 1, 2023·0 cites·19 claims
- 2058US2024197729A1ALK-5 Inhibitors and Uses ThereofSUMITOMO PHARMA ONCOLOGY INC·Filed 2022·Application pending·0 cites
- 2157US2024091226A1Forms and Formulations Of A Tyrosine Kinase Non-Receptor 1 (TNK1) InhibitorSUMITOMO PHARMA ONCOLOGY INC·Filed 2022·Application pending·0 cites
- 2256US11746103B2ALK-5 inhibitors and uses thereofSUMITOMO PHARMA ONCOLOGY INC·Filed 2022·Granted Sep 5, 2023·0 cites·27 claims
- 2353US2023090742A1Aminopyrimidinylaminobenzonitrile derivatives as nek2 inhibitorsSUMITOMO PHARMA ONCOLOGY INC·Filed 2021·Application pending·0 cites
- 2452US11529350B2Tyrosine kinase non-receptor 1 (TNK1) inhibitors and uses thereofSUMITOMO PHARMA ONCOLOGY INC·Filed 2020·Granted Dec 20, 2022·0 cites·51 claims
- 2548US2024382473A1Combination Therapies for Treatment of Myelodysplastic SyndromeSUMITOMO PHARMA ONCOLOGY INC·Filed 2020·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when SUMITOMO PHARMA ONCOLOGY INC files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →